CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Daylight Saving Time Begins March 10, 2019. As a friendly reminder, airlines often change their rout...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
Just a reminder that the revised client forms implement today! Don't forget to toss your o...
After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...
Reminder test emails for the Health and Human Services (HHS) email notifications for WNV reactives h...
Honor Your StaffCelebrate Lab Week, and honor yourself and your colleagues as a vital part of the la...